Pulmonary nodules: experimental and clinical studies at low-dose CT.

PURPOSE: To compare the number of pulmonary nodules detected at helical low- and standard-dose computed tomography (CT) and to investigate the diagnostic value of low-dose CT with a radiation exposure equivalent to that used at chest radiography. MATERIALS AND METHODS: Two radiologists recorded pulmonary nodules at standard-dose (250 or 100 mA, pitch of 1; 200 mA, pitch of 2) or low-dose CT (50 or 25 mA, pitch of 1 or 2) in five postmortem specimens and 75 patients. Nodules were assessed by size (5 mm or smaller, 6-10 mm, or larger than 10 mm) and by diagnostic confidence ("definite nodule," "definite lesion, not classic nodule," or "questionable lesion, possibly representing a vessel") with the Wilcoxon signed rank test. Artifacts depicted at low-dose CT were recorded. RESULTS: There were no statistically significant differences in the number of nodules detected at standard- or low-dose CT except in nodules 5 mm or smaller that were assessed as definite nodules at standard- or low-dose CT (25 mA, pitch of 2) (472 vs 397, P < .05). Artifacts that possibly interfered with nodule detection were observed exclusively at CT with 25 mA and a pitch of 2. CONCLUSION: Pulmonary nodules were detected reliably at CT with 50 mA and pitch of 2 or with 25 mA and a pitch of 1. However, further reduction of the dose to that used at chest radiography was associated with a significant decrease in the number of nodules 5 mm or smaller that were detected, possibly due to artifacts.

Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma.

PDN-21 (katacalcin), a peptide from the calcitonin (CT) gene, was measured in plasma from healthy persons and patients with medullary thyroid carcinoma (MTC). PDN-21 was detectable (greater than or equal to 10 ng/l) in 73% of normal persons (n = 40). In 17 normal persons with undetectable basal plasma levels, PDN-21 became detectable (greater than or equal to 10 ng/l) by stimulation with iv pentagastrin in 7 cases. Basal levels were more often detectable in men than in women. In 65 patients with MTC, PDN-21 levels were highly correlated with CT levels as determined by an "in house" RIA (r = 0.99); the mean ratio of CT/PDN-21, on a molar base, was 0.96 +/- 0.33 over the entire range. In iv stimulation tests with pentagastrin, PDN-21 and CT showed good parallelism (mean ratio of CT/PDN-21: 1.1 +/- 0.62); in MTC patients with normal basal levels, however, peak to basal ratios during iv pentagastrin testing were higher for PDN-21 than for CT, due to the more sensitive PDN-21 assay. In a selective venous catheter study of a patient with MTC, the mean CT/PDN-21 ratio for all samples was 1.04 +/- 0.12, but the peak to peripheral levels were higher for PDN-21 (4.1-fold) than for CT (2.8-fold). In conclusion, determination of PDN-21 by RIA is equivalent to determination of CT in diagnosing MTC patients. In few patients, it might be even slightly more sensitive. PDN-21 should be determined in all cases with borderline CT results.